Sökning: WFRF:(Spaak Jonas)
> Engstrøm Thomas >
Intravenous beta-bl...
Intravenous beta-blocker therapy in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention is not associated with benefit regarding short-term mortality : a Swedish nationwide observational study
-
- Mohammad, Moman A. (författare)
- Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular Cardiology,Lund University Research Groups,Skåne University Hospital
-
- Andell, Pontus (författare)
- Lund University,Lunds universitet,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Molecular Cardiology,Lund University Research Groups,Skåne University Hospital
-
- Koul, Sasha (författare)
- Lund University,Lunds universitet,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Molecular Cardiology,Lund University Research Groups,Skåne University Hospital
-
visa fler...
-
- Desta, Liyew (författare)
- Karolinska Institutet
-
- Jernberg, Tomas (författare)
- Karolinska Institutet,Karolinska Institute
-
- Omerovic, Elmir (författare)
- Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden
-
- Spaak, Jonas (författare)
- Karolinska Institutet
-
- Fröbert, Ole, 1964- (författare)
- Örebro University,Region Örebro län,Örebro universitet, Institutionen för medicinska vetenskaper,Department of Cardiology, Örebro University Hospital, Örebro, Sweden
-
- Jensen, Jens (författare)
- Karolinska Institutet,Karolinska Institute
-
- Engstrøm, Thomas (författare)
- The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
-
- Hofman-Bang, Claes (författare)
- Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
-
- Persson, Hans (författare)
- Karolinska Institutet
-
- Erlinge, David (författare)
- Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular Cardiology,Lund University Research Groups,Skåne University Hospital
-
visa färre...
-
(creator_code:org_t)
- Europa Edition, 2017
- 2017
- Engelska.
-
Ingår i: EuroIntervention. - : Europa Edition. - 1774-024X .- 1969-6213. ; 13:2, s. E210-E218
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.4...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aims: Our aim was to investigate the impact of intravenous (IV) beta-blocker therapy on short-term mortality and other in-hospital events in patients with ST-segment elevation myocardial infarction (STEMI) treated with dual antiplatelet therapy (DAPT) and primary percutaneous coronary intervention (PCI).Methods and results: Using the nationwide Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) registry, we identified all patients with STEMI undergoing PCI between 2006 and 2013. Patients with cardiogenic shock and cardiac arrest at presentation were excluded. The primary endpoint was mortality within 30 days. Secondary endpoints were in-hospital events (mortality, cardiogenic shock and left ventricular ejection fraction [LVEF] <40% at discharge). We adjusted for confounders with a multivariable model and propensity score matching. Out of 16,909 patients, 2,876 (17.0%) were treated with an IV beta-blocker. After adjusting for confounders, the IV beta-blocker group had higher 30-day all-cause mortality (HR: 1.44, 95% CI: 1.14-1.83), more in-hospital cardiogenic shock (OR: 1.53, 95% CI: 1.09-2.16) and were more often discharged with an LVEF <40% (OR: 1.70, 95% CI: 1.51-1.92).Conclusions: In this large nationwide observational study, the use of IV beta-blockers in patients with STEMI treated with primary PCI was associated with higher short-term mortality, lower LVEF at discharge, as well as a higher risk of in-hospital cardiogenic shock.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- adjunctive pharmacotherapy
- clinical research
- ST-segment elevation myocardial infarction (STEMI)
- Adjunctive pharmacotherapy
- Clinical research
- ST-segment elevation myocardial infarction (STEMI)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Mohammad, Moman ...
-
Andell, Pontus
-
Koul, Sasha
-
Desta, Liyew
-
Jernberg, Tomas
-
Omerovic, Elmir
-
visa fler...
-
Spaak, Jonas
-
Fröbert, Ole, 19 ...
-
Jensen, Jens
-
Engstrøm, Thomas
-
Hofman-Bang, Cla ...
-
Persson, Hans
-
Erlinge, David
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
EuroIntervention
- Av lärosätet
-
Örebro universitet
-
Lunds universitet
-
Karolinska Institutet